COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA

Pagano, Livio; Salmanton‐García, Jon; Marchesi, Francesco; López‐García, Alberto; Lamure, Sylvain; Itri, Federico; Silva, Maria Gomes da; Dragonetti, Giulia; Falces‐Romero, Iker; Doesum, Jaap van; Sili, Uluhan; Labrador, Jorge; Calbacho, M.; Bilgin, Yavuz M.; Weinbergerová, Barbora; Gomez, Laura Milena Serrano; Ribera, Josep‐María; Malak, Sandra; Loureiro-Amigo, José; Glenthøj, Andreas; Córdoba, Raúl; Nunes-Rodrigues, Raquel; González-López, Tomás José; Karlsson, Linda; Jiménez, María-José; Hernández‐Rivas, José‐Ángel; Jakšić, Ozren; Ráčil, Zdeněk; Busca, Alessandro; Corradini, Paolo; Hoenigl, Martin; Климко, Н Н; Köehler, Philipp; Pagliuca, Antonio; Passamonti, Francesco; Cornely, Oliver A.

doi:10.1182/blood.2021014124

Cited by 87 publications

(123 citation statements)

References 22 publications

Supporting

Mentioning

108

Contrasting

Order By: Relevance

“…These studies also reported cases of breakthrough infections in partially or completely vaccinated patients. [65][66][67][68][69][70][71][72][73][74][75][76][77][78][79] A comprehensive workup of SARS-CoV- HM) and demonstrated a high booster-induced seroconversion of 56%, even in patients that were previously treated for their malignancy. 80 Prior BTKi or anti-CD20 treatment was associated with inferior postbooster seroconversion and anti-S IgG titers.…”

Section: Covidmentioning

confidence: 99%

COVID-19 in patients with hematologic malignancy

Langerbeins

Hallek

2022

Blood

View full text Add to dashboard Cite

The coronavirus infectious disease (COVID-19) shows a remarkable symptomatic heterogeneity. Several risk factors including advanced age, previous illnesses and a compromised immune system contribute to an unfavorable outcome. In patients with hematologic malignancy, the immune response to severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is significantly reduced explaining why the mortality rate of hematologic patients hospitalized for a SARS-CoV-2 infection is about 34%. Active immunization is an essential pillar to prevent SARS-CoV-2 infections in patients with hematologic malignancy. However, the immune response to SARS-CoV-2 vaccines may be significantly impaired, as only half of patients with hematologic malignancy develop a measurable anti-viral antibody response. The subtype of hematologic malignancy and B-cell depleting treatment predict a poor immune response to vaccination. Recently, antiviral drugs and monoclonal antibodies for pre-exposure or post-exposure prophylaxis and for early treatment of COVID-19 have become available. These therapies should be offered to patients at high risk for severe COVID-19 and vaccine non-responder. Importantly, as the virus evolves, some therapies may lose their clinical efficacy against new variants. Therefore, the ongoing pandemic will remain a major challenge for patients with hematologic malignancy and their caregivers who need to constantly monitor the scientific progress in this area.

show abstract

Section: Covidmentioning

confidence: 99%

COVID-19 in patients with hematologic malignancy

Langerbeins

Hallek

2022

Blood

View full text Add to dashboard Cite

show abstract

“…Interestingly, this discordant response seems to be more prevalent with BNT162b2 (BioNTech, Pfizer) and not mRNA-1273 (Moderna) [ 92 ]. Despite these challenges, a significant decrease in overall mortality has been reported for patients with hematologic malignancies and COVID-19 in the postvaccination period compared to pre-vaccination at 12.4% versus 31%, respectively [ 93 ]. Recent novel developments in the use of monoclonal antibodies for pre-exposure prophylaxis in immunocompromised patients are promising.…”

Section: Covid-19 Therapeutics In Patients With Hematologic Malignanciesmentioning

confidence: 99%

COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments

et al. 2022

View full text Add to dashboard Cite

Patients with hematologic malignancies are particularly vulnerable to infections due to underlying humoral and cellular immune dysfunction, cytotoxic chemotherapy regimens, advanced age, and the presence of comorbid conditions. Infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic, has become a leading cause of death globally and has disproportionally affected this high-risk population. Here, we review the cumulative evidence demonstrating worse outcomes for patients with hematologic malignancies when compared to patients with solid tumors and the general population. We examine risk factors shared with the general population (age, sex, comorbid conditions, race) and those that are cancer-specific (cytotoxic chemotherapy, progressive disease, cancer type), all of which confer an increased risk of severe COVID-19. Despite the historical exclusion of cancer patients from COVID-19 therapy trials, we review the emerging evidence that patients with hematologic malignancies benefit from specific treatments such as convalescent plasma. Although COVID-19 vaccines are significantly less effective in this patient population, encouraging results are observed in a subset of these patients after receiving a booster dose.

show abstract

“…Following title/abstract screening, 479 articles were excluded. Of the remaining 90 publications, 62 studies fulfilled the eligibility criteria and 28 were excluded due to the following reasons: eight studies were not related to our topic [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , seven studies provided not enough data in the case of seropositiviness after immunization [31] , [32] , [33] , [34] , [35] , [36] , [37] , four studies evaluated the immunogenicity of a third dose [38] , [39] , [40] , [41] , two studies were conference abstracts [42] , [43] , two studies were case reports [44] , [45] , two studies reported the cellular outcomes solely [46] , [47] , one study reanalyzed the data of the same included studies (48) , one study was a protocol of an original article (49) , and one study was commentary (50) . Furthermore, 20 additional articles were retrieved from other sources, resulting in inclusion of 82 potential studies to be included in the final analysis ( Figure 1 ).…”

Section: Resultsmentioning

confidence: 99%